The Somatic Mosaicism across Human Tissues Network
- PMID: 40604182
- DOI: 10.1038/s41586-025-09096-7
The Somatic Mosaicism across Human Tissues Network
Abstract
From fertilization onwards, the cells of the human body acquire variations in their DNA sequence, known as somatic mutations. These postzygotic mutations arise from intrinsic errors in DNA replication and repair, as well as from exposure to mutagens. Somatic mutations have been implicated in some diseases, but a fundamental understanding of the frequency, type and patterns of mutations across healthy human tissues has been limited. This is primarily due to the small proportion of cells harbouring specific somatic variants within an individual, making them more challenging to detect than inherited variants. Here we describe the Somatic Mosaicism across Human Tissues Network, which aims to create a reference catalogue of somatic mutations and their clonal patterns across 19 different tissue sites from 150 non-diseased donors and develop new technologies and computational tools to detect somatic mutations and assess their phenotypic consequences, including clonal expansions. This strategy enables a comprehensive examination of the mutational landscape across the human body, and provides a comparison baseline for somatic mutation in diseases. This will lead to a deep understanding of somatic mutations and clonal expansions across the lifespan, as well as their roles in health, in ageing and, by comparison, in diseases.
© 2025. Springer Nature Limited.
Conflict of interest statement
Competing interests: F.C. is an academic founder of Curio Biosciences and Doppler Biosciences, and scientific advisor for Amber Bio; F.C’s interests were reviewed and managed by the Broad Institute in accordance with their conflict-of-interest policies. G.G. receives research funds from IBM, Pharmacyclics/Abbvie, Bayer, Genentech, Calico, Ultima Genomics, Inocras, Google, Kite and Novartis; is an inventor on patent applications filed by the Broad Institute related to MSMuTect, MSMutSig, POLYSOLVER, SignatureAnalyzer-GPU, MSEye and MinimuMM-seq; is a founder, consultant and holds privately held equity in Scorpion Therapeutics and PreDICTA Biosciences; and was a consultant to Merck, all unrelated to the present work. E.E.E. is a scientific advisory board member of Variant Bio. C.Z. is a co-founder and equity holder of Pioneer Genomics and reports that Baylor College of Medicine filed a patent application related to the CompDuplex-seq or CompDup method. P.N. reports research grants from Allelica, Amgen, Apple, Boston Scientific, Cleerly, Genentech/Roche, Ionis, Novartis and Silence Therapeutics; personal fees from Allelica, Apple, AstraZeneca, Bain Capital, Blackstone Life Sciences, Bristol Myers Squibb, Creative Education Concepts, CRISPR Therapeutics, Eli Lilly & Co, Esperion Therapeutics, Foresite Capital, Foresite Labs, Genentech/Roche, GV, HeartFlow, Magnet Biomedicine, Merck, Novartis, Novo Nordisk, TenSixteen Bio and Tourmaline Bio; equity in Bolt, Candela, Mercury, MyOme, Parameter Health, Preciseli and TenSixteen Bio; and spousal employment at Vertex Pharmaceuticals, all unrelated to the present work. C.T. is the founder of C2T; a consultant for Bayer; a member of the scientific advisory board of PrognomiQ; and receives royalties from Exact Sciences. J.W.O. is the founder and CEO of Absolute DNA, with no direct relation to this study, and the interests are managed by University-Industry Foundation in Yonsei University Health System in accordance with their conflict-of-interest policies. E.A.L. is a member of the scientific advisory board for Inocras. All other authors declare no competing interests.
References
-
- International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 409, 860–921 (2001). - DOI
Publication types
MeSH terms
Grants and funding
- R01 HG012384/HG/NHGRI NIH HHS/United States
- R01 CA267872/CA/NCI NIH HHS/United States
- P30 CA043703/CA/NCI NIH HHS/United States
- UG3 NS132061/NS/NINDS NIH HHS/United States
- UG3 NS132136/NS/NINDS NIH HHS/United States
- R00 HG012956/HG/NHGRI NIH HHS/United States
- R01 HG009658/HG/NHGRI NIH HHS/United States
- UG3 NS132084/NS/NINDS NIH HHS/United States
- UM1 DA058229/DA/NIDA NIH HHS/United States
- R01 DK131437/DK/NIDDK NIH HHS/United States
- UH3 NS132084/NS/NINDS NIH HHS/United States
- UG3 NS132146/NS/NINDS NIH HHS/United States
LinkOut - more resources
Full Text Sources
